Expired activity
Please go to the PowerPak homepage and select a course.

Taking the Pulse of Undiagnosed Atrial Fibrillation: Pharmacists as a Lynchpin of Detection and Team-Based Care

This activity is sponsored by PVI, PeerView Institute for Medical Education

This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.

Release Date

May 6, 2022

Expiration Date

May 5, 2023

Time to Complete Activity

60 minutes


Enduring Material

Activity Description

Screening and diagnosing atrial fibrillation (AF) is vital to implementing guideline-recommended treatment to reduce the risk of stroke. In this activity, an expert panel of pharmacists and a cardiologist discuss risk factors for AF, evidence-based strategies for screening and managing asymptomatic and symptomatic AF, and how multidisciplinary and interdisciplinary approaches to care increase screening and improve patient outcomes.

Target Audience

This activity has been designed to meet the educational needs of pharmacists, cardiologists, primary care physicians, and other clinicians involved in the care of patients with, or at risk for, AF.

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Identify ways that pharmacists can work collaboratively with other clinical colleagues to bridge the gap between patients and healthcare team professionals to improve AF screening, diagnosis, and treatment
  • Screen individuals who are at risk for stroke due to undiagnosed AF and refer them for further evaluation and treatment, as appropriate
  • Collaborate with clinical colleagues to ensure that evidence-based, guideline-recommended treatment is discussed and offered to patients with AF to reduce the risk of stroke
  • Educate patients with AF about the heightened risk of stroke and the importance of anticoagulation therapy

disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Joe R. Anderson, PharmD, PhC
Assistant Dean for Curricular Affairs
Associate Professor of Pharmacy Practice
University of New Mexico College of Pharmacy
Albuquerque, New Mexico

Joe R. Anderson, PharmD, PhC, has no financial interests/relationships or affiliations in relation to this activity.

Barry E. Bleske, PharmD, FCCP
Professor and Chair
Pharmacy Practice & Administrative Sciences
University of New Mexico
College of Pharmacy
Professor Emeritus, University of Michigan, College of Pharmacy
Albuquerque, New Mexico

Barry E. Bleske, PharmD, FCCP, has no financial interests/relationships or affiliations in relation to this activity.

Abinash Achrekar, MD, MPH
Vice Chair of Medicine
Associate Professor
Division of Cardiology
University of New Mexico
Albuquerque, New Mexico

Abinash Achrekar, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with Bristol Myers Squibb.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Margery Tamas, MD
PVI, PeerView Institute for Medical Education

Margery Tamas, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant for Fresenius Medical Care North America.


JAPIn support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-22-003-H01-P

Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

Participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity's topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2022, PeerView